With the rapid pace of immunologic research, it is more important than ever for readers to understand rational immunodiagnosis, immunoprophylaxis, and immunotherapy. This column is intended to help you carry out proper immunologic drug use in your practice.
Get full access to this article
View all access options for this article.
References
1.
GrabensteinJ.D.Anaphylaxis: Epinephrine and emergency responses. Hosp Pharm.1997; 32: 1377–8, 1382–4,1387–9.
2.
WiederholtW.C., MulderD.W., LambertE.H.The Landry-Guillain-Barré-Strohl syndrome or polyradiculoneuropathy: Historical review, report on 97 patients, and present concepts. Mayo Clin Proc.1964; 39: 427–51.
HughesR.A.C., ReesJ.H.Clinical and epidemiologic features of Guillain-Barré syndrome. J Infect Dis.1997; 176(suppl 2): S92–8.
5.
SteinbergJ.S.Guillain-Barré Syndrome: An Overview for the Layperson.9th ed.Wynnewood, PA: Guillain-Barré Syndrome Foundation International; 2000.
6.
TuttleJ., ChenR.T., RantalaH.The risk of Guillain-Barré syndrome after tetanus-toxoid-containing vaccines in adults and children in the United States. Am J Public Health.1997; 87: 2045–8.
7.
LaskyT., TerraccianoG.J., MagderL.The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med.1998; 339: 1797–802.
8.
LangD.R., AllosB.M., BlaserM.J.Workshop summary and recommendations regarding the development of Guillain-Barré syndrome following Campylobacter infection. J Infect Dis.1997; 176(suppl 2): S198–200.
RatkoT.A., BurnettD.A., FoulkeG.E.Recommendations for off-label use of intravenously administered immunoglobulin preparations. JAMA.1995; 273: 1865–70.
13.
DalakasM.Intravenous immune globulin therapy for neurologic diseases. Ann Intern Med.1997; 126: 721–30.
14.
GrabensteinJ.D.ImmunoFacts: Vaccines and Immunologic Drugs. 21st rev. Saint Louis: Facts and Comparisons, Inc.; February 2001.
15.
NagpalS., BensteadT., ShumakK.Treatment of Guillain-Barré syndrome: A cost-effectiveness analysis. J Clin Apheresis.1999; 14: 107–13.
16.
GrabensteinJ.D.Side effects: A consumer's guide to cause and effect. Hosp Pharm.2000; 35: 1308–16.
17.
SchoenbergB.S.Epidemiology of Guillain-Barré syndrome. Adv Neurol.1978; 19: 249–30.
18.
HollidayP., BauerR.Polyradiculoneuritis secondary to immunization with tetanus and diphtheria toxoids. Arch Neurol.1983; 40: 56–7.
19.
StrattonK.R., HoweC.J., JohnstonR.B.Jr., eds. Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality.Washington, DC: National Academy Press; 1994, 464.
20.
AwongI.E., DandurandK.R., KeeysC.A.Drug-associated Guillain-Barré syndrome: A literature review. Ann Pharmacother.1996; 30: 173–80.
21.
HughesR., ReesJ., SmeetonN., WinerJ.Vaccines and Guillain-Barré syndrome. BMJ.1996; 312: 1475–6.
22.
DaSilveiraC.M., SalisburyD.M., DeQuadrosC.A.Measles vaccination and Guillain-Barré syndrome. Lancet.1997; 349: 14–15.
23.
FenichelG.M.Neurologic risk of immunization: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology.1999; 52: 1546–52.
GrabensteinJ.D.Pandemic influenza: Planning now to avoid another tragedy. Hosp Pharm.1999; 34: 845–6, 849-51,855-6.
26.
SilversteinA.M.Pure Politics and Impure Science: The Swine Flu Affair.Baltimore: Johns Hopkins University Press; 1981.
27.
NeustadtR.E., FinebergH V.The Epidemic That Never Was: Policy-Making and The Swine Flu Affair.New York: Vintage Books; 1983.
28.
GriffenhagenG.The swine flu vaccine saga. J Am Pharm Assoc.1976; 16: 439–43.
29.
ParkmanP.D., GalassoG.J., TopF.H.Jr.Summary of clinical trials of influenza vaccines. J Infect Dis.1976; 134: 100–7.
30.
RubinD.M., HendyV.Swine influenza and the news media. Ann Intern Med.1977; 87: 769–74.
31.
WadeN.1976 swine flu campaign faulted yet principals would do it again. Science.1978; 202: 849, 851–2.
32.
HillemanM.R.Cooperation between government and industry in combating a perceived emerging pandemic: The 1976 swine influenza vaccination program. JAMA.1996; 275: 241–3.
33.
BoffeyP.M.Swine flu: Were the three deaths in Pittsburgh a coincidence?Science.1976; 194: 590–1, 648.
WebsterR.G.Predictions for future human influenza pandemics. J Infect Dis.1997; 176(suppl 1): S14–19.
36.
KolataG.Flu: The Story of the Great Influenza Pandemic of 1918 and the Search for the Virus that Caused It.New York: Farrar, Strous & Giroux; 1999, 167–85.
37.
SchonbergerL.B., BregmanD.J., Sullivan-BolyaiJ.Z.Guillain-Barré syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol.1979; 110: 105–23.
38.
SafranekT.J., LawrenceD.N., KurlandL.T.Reassessment of the association between Guillain-Barré syndrome and receipt of swine influenza vaccine in 1976-1977: Results of a two-state study. Am J Epidemiol.1991; 133: 940–51.
39.
GrabensteinJ.D.Compensation for vaccine injury: Balancing society's need and personal risk. Hosp Pharm.1995; 30: 831–2, 834–6.
40.
MarksJ.S., HalpinT.J.Guillain-Barré syndrome in recipients of A/New Jersey influenza vaccine. JAMA.1980; 243: 2490–4.
41.
LangmuirA.D., BregmanD.J., KurlandL.T.An epidemiologic and clinical evaluation of Guillain-Barré syndrome reported in association with the administration of swine influenza vaccines. Am J Epidemiol.1984; 119: 841–79.
42.
BremenJ.G., HaynerN.S.Guillain-Barré syndrome and its relationship to swine influenza vaccination in Michigan, 1976–77. Am J Epidemiol.1984; 119: 880–9.
43.
HurwitzE.S., SchonbergerL.B., NelsonD.B.Guillain-Barré syndrome and the 1978-1979 influenza vaccine. N Engl J Med.1981; 304: 1557–61.
44.
KaplanJ.E., KatonaP., HurwitzE.S.Guillain-Barré syndrome in the United States,1979-1980 and 1980-1981: Lack of an association with influenza vaccination. JAMA.1982; 248: 698–700.
45.
RoscelliJ.D., BassJ.W., PangL.Guillain-Barré syndrome and influenza vaccination in the US Army, 1980–1988. Am J Epidemiol.1991; 133: 952–5.
46.
ChenR., KentJ., RhodesP.Investigation of a possible association between influenza vaccination and Guillain-Barré syndrome in the United States, 1990-91 [abstract]. Post Market Surveil.1992; 6: 5–6.
47.
Advisory Committee on Immunization Practices.Control and Prevention of Anthrax in the United States. MMWR.2000; 49.
48.
ShawF.E.Jr., GrahamD.J., GuessH.A.Postmarketing surveillance for neurologic adverse events reported after hepatitis B vaccination—Experience of the first three years. Am J Epidemiol.1988; 127: 337–52.
49.
KinnunenE., JunttilaO., HaukkaJ.Nationwide oral poliovirus vaccination campaign and the incidence of Guillain-Barré syndrome. Am J Epidemiol.1998; 147: 69–73.
50.
RutledgeS.L., SneadOC.IIINeurologic complications of immunizations. J Pediatr.1986; 109: 917–24.
51.
Advisory Committee on Immunization Practices.Update: Vaccine side effects, adverse reactions, contraindications, and precautions. MMWR.1996; 45(RR-12): 1–35, errata 227.
52.
ScottD.A.Vaccines against Campylobacter jejuni.J Infect Dis.1997; 176(suppl 2): S183–8.
